Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant Pharma, a specialty pharmaceutical company that develops, manufactures and markets pharmaceutical products in the areas of neurology and dermatology, has re-launched Oxsoralen-Ultra, its therapy for severe psoriasis, in the US on a limited supply basis.
Subscribe to our email newsletter
Valeant Pharma said that, since last year, it has experienced a shortage of Oxsoralen products due to an unanticipated change in the supplier of the product’s active ingredient.
Valeant Pharma stated that patients can obtain Oxsoralen-Ultra (Methoxsalen capsules, USP, 10mg) with a prescription through their local pharmacies who is expected to work with their wholesalers to arrange for shipment.
Rajiv De Silva, chief operating officer of specialty pharmaceuticals at Valeant Pharma, said: “Valeant understands the importance of Oxsoralen-Ultra to patients suffering from psoriasis, and we have been working in partnership with the FDA to address the drug shortage.
“We are pleased to be able to begin re-supplying Oxsoralen-Ultra to physicians and their patients on a limited basis and apologise for any issues this shortage has caused. Valeant is committed to promptly getting this product back on pharmacy shelves.”